Di Fonte R - Search Results

1

Plasma-activated medium triggers cell death and the presentation of immune activating danger signals in melanoma and pancreatic cancer cells.

Azzariti A, Iacobazzi RM, Di Fonte R, Porcelli L, Gristina R, Favia P, Fracassi F, Trizio I, Silvestris N, Guida G, Tommasi S, Sardella E. Azzariti A, et al. Among authors: di fonte r. Sci Rep. 2019 Mar 11;9(1):4099. doi: 10.1038/s41598-019-40637-z. Sci Rep. 2019. PMID: 30858524 Free PMC article.

2

Targeting human liver cancer cells with lactobionic acid-G(4)-PAMAM-FITC sorafenib loaded dendrimers.

Iacobazzi RM, Porcelli L, Lopedota AA, Laquintana V, Lopalco A, Cutrignelli A, Altamura E, Di Fonte R, Azzariti A, Franco M, Denora N. Iacobazzi RM, et al. Among authors: di fonte r. Int J Pharm. 2017 Aug 7;528(1-2):485-497. doi: 10.1016/j.ijpharm.2017.06.049. Epub 2017 Jun 15. Int J Pharm. 2017. PMID: 28624661

3

Synthesis and biological evaluation of N-biphenyl-nicotinic based moiety compounds: A new class of antimitotic agents for the treatment of Hodgkin Lymphoma.

Porcelli L, Stolfa D, Stefanachi A, Di Fonte R, Garofoli M, Iacobazzi RM, Silvestris N, Guarini A, Cellamare S, Azzariti A. Porcelli L, et al. Among authors: di fonte r. Cancer Lett. 2019 Mar 31;445:1-10. doi: 10.1016/j.canlet.2018.12.013. Epub 2018 Dec 22. Cancer Lett. 2019. PMID: 30583077

4

CAFs and TGF-β Signaling Activation by Mast Cells Contribute to Resistance to Gemcitabine/Nabpaclitaxel in Pancreatic Cancer.

Porcelli L, Iacobazzi RM, Di Fonte R, Serratì S, Intini A, Solimando AG, Brunetti O, Calabrese A, Leonetti F, Azzariti A, Silvestris N. Porcelli L, et al. Among authors: di fonte r. Cancers (Basel). 2019 Mar 7;11(3):330. doi: 10.3390/cancers11030330. Cancers (Basel). 2019. PMID: 30866547 Free PMC article.

5

Gene Expression Comparison between the Lymph Node-Positive and -Negative Reveals a Peculiar Immune Microenvironment Signature and a Theranostic Role for WNT Targeting in Pancreatic Ductal Adenocarcinoma: A Pilot Study.

Argentiero A, De Summa S, Di Fonte R, Iacobazzi RM, Porcelli L, Da Vià M, Brunetti O, Azzariti A, Silvestris N, Solimando AG. Argentiero A, et al. Among authors: di fonte r. Cancers (Basel). 2019 Jul 4;11(7):942. doi: 10.3390/cancers11070942. Cancers (Basel). 2019. PMID: 31277479 Free PMC article.

6

The β-adrenergic receptor antagonist propranolol offsets resistance mechanisms to chemotherapeutics in diverse sarcoma subtypes: a pilot study.

Porcelli L, Garofoli M, Di Fonte R, Fucci L, Volpicella M, Strippoli S, Guida M, Azzariti A. Porcelli L, et al. Among authors: di fonte r. Sci Rep. 2020 Jun 26;10(1):10465. doi: 10.1038/s41598-020-67342-6. Sci Rep. 2020. PMID: 32591592 Free PMC article.

7

Hydroxy-Propil-β-Cyclodextrin Inclusion Complexes of two Biphenylnicotinamide Derivatives: Formulation and Anti-Proliferative Activity Evaluation in Pancreatic Cancer Cell Models.

Iacobazzi RM, Cutrignelli A, Stefanachi A, Porcelli L, Lopedota AA, Di Fonte R, Lopalco A, Serratì S, Laquintana V, Silvestris N, Franco M, Cellamare S, Leonetti F, Azzariti A, Denora N. Iacobazzi RM, et al. Among authors: di fonte r. Int J Mol Sci. 2020 Sep 7;21(18):6545. doi: 10.3390/ijms21186545. Int J Mol Sci. 2020. PMID: 32906812 Free PMC article.

8

Active notch protects MAPK activated melanoma cell lines from MEK inhibitor cobimetinib.

Porcelli L, Mazzotta A, Garofoli M, Di Fonte R, Guida G, Guida M, Tommasi S, Azzariti A. Porcelli L, et al. Among authors: di fonte r. Biomed Pharmacother. 2021 Jan;133:111006. doi: 10.1016/j.biopha.2020.111006. Epub 2020 Nov 14. Biomed Pharmacother. 2021. PMID: 33202284 Free article.

9

uPAR⁺ extracellular vesicles: a robust biomarker of resistance to checkpoint inhibitor immunotherapy in metastatic melanoma patients.

Porcelli L, Guida M, De Summa S, Di Fonte R, De Risi I, Garofoli M, Caputo M, Negri A, Strippoli S, Serratì S, Azzariti A. Porcelli L, et al. Among authors: di fonte r. J Immunother Cancer. 2021 May;9(5):e002372. doi: 10.1136/jitc-2021-002372. J Immunother Cancer. 2021. PMID: 33972390 Free PMC article.

10

The ERRα-VDR axis promotes calcitriol degradation and estrogen signaling in breast cancer cells, while VDR-CYP24A1-ERRα overexpression correlates with poor prognosis in patients with basal-like breast cancer.

Danza K, Porcelli L, De Summa S, Di Fonte R, Pilato B, Lacalamita R, Serratì S, Azzariti A, Tommasi S. Danza K, et al. Among authors: di fonte r. Mol Oncol. 2022 Feb;16(4):904-920. doi: 10.1002/1878-0261.13013. Epub 2021 Jul 16. Mol Oncol. 2022. PMID: 34003583 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

28 results

Search Page